newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

  • Ascentage Pharma Group International (NASDAQ: AAPG, HKEX: 6855) announced that its management will participate in four investor conferences in New York, NY.
  • The company will attend Citi's 2026 Biopharma Back to School Conference on September 9, 2026, from 4:20 p.m. to 4:55 p.m. ET at the JW Marriott Essex House.
  • Ascentage Pharma will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, from 9:00 a.m. to 9:30 a.m. ET at the Lotte New York Palace Hotel.
  • The company is scheduled to speak at the Deutsche Bank 2026 Healthcare Summit on September 16-17, 2026, at the Deutsche Bank Center.
  • Ascentage Pharma will also participate in the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum on September 23-24, 2026, in New York, NY.
  • The company focuses on discovering, developing, 4 commercializing novel therapies for cancer, including inhibitors targeting Bcl-2, MDM2-p53, 4 next-generation kinase inhibitors, 4 protein degraders.
  • Olverembatinib is the company's first approved product, a third-generation BCR-ABL1 inhibitor approved in China for chronic myeloid leukemia (CML) patients with T315I mutations or resistance to prior TKIs.
  • Registrational Phase III trials for Olverembatinib include POLARIS-2 for CML, POLARIS-1 for Ph+ ALL, 4 POLARIS-3 for SDH-deficient GIST patients.
  • Lisaftoclax is the company's second approved product, a Bcl-2 inhibitor approved in China for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients previously treated with BTK inhibitors.
  • Global registrational Phase III trials for Lisaftoclax include GLORA, GLORA-2, GLORA-3, 4 GLORA-4 studies across various hematologic malignancies.
  • The company holds intellectual property rights 4 has established partnerships with major pharmaceutical firms including Takeda, AstraZeneca, Merck, Pfizer, 4 Innovent.
  • Ascentage Pharma has collaborated with leading research institutions such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute, 4 University of Michigan.
  • The press release includes forward-looking statements subject to risks 4 uncertainties that could cause actual results to differ materially from expectations.